From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Chimerix Speeding Up Brincidofovir Trials for Ebola

by Global Biodefense Staff
October 16, 2014
Brincidofovir as a Treatment for Ebola Virus

Credit: Shutterstock

Chimerix reported today that it has received approval from the U.S. Food and Drug Administration to launch a Phase 2 clinical trial of Brincidofovir for the treatment of Ebola virus.

Earlier this month, Chimerix was granted Emergency Investigational New Drug (EIND) status for Brincidofovir (CMX001) for use in patients with Ebola virus. The drug has already been administered to two Ebola patients, including Thomas Eric Duncan.

The new trial will test safety, tolerability and efficacy for Brincidofovir.

“We want to do our part first to determine if there is a role for Brincidofovir, we do have emergency INDs that are currently in place and we do have a protocol that is under review at the FDA to be finalized under a new IND by the end of this week,” said Chimerix CEO Michelle Berrey in a corporate update to analysts.

“We are working to identify the key hospitals, the key medical centers where we believe that protocol should be implemented where we know they have adequate training; they have adequate facilities to be caring for individual who are confirmed to be infected with Ebola virus and to our appropriate candidates for Brincidofovir,” stated Berrey.

Wide-Ranging Utility of Brincidofovir

Brincidofovir is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenoviruses. The drug has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date, side effects that can be treatment limiting with currently available antivirals.

Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix’s initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients.

Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial.

BARDA Backing for Investigation as Smallpox Countermeasure

Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

The FDA has authorized a Phase 2 protocol for investigating Brincidofovir to begin immediately. Chimerix stated that Brincidofovir tablets are available for immediate use in clinical trials.

From Our Partners
Tags: AdenovirusAntiviralsASPRBARDAEbolaHHSSmallpox

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC